At the forefront of therapies for rare and orphan diseasesTM
HOME CONTACT US         
Share
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
 
Investors
 



Home >> Investor Relations >> Investor Relations

Investor Relations

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus’ lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

View all »Recent Releases

Jan 26, 2015
Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium

Jan 12, 2015
Amicus Therapeutics Provides Full-Year 2015 Strategic Outlook and Financial Guidance

View all »Events & Presentations

Jan 13, 2015 at 1:30 PM ET
33rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2015 at 7:30 AM ET
Migalastat Monotherapy Phase 3 Cardiac Data


Copyright © 2015 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy